One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2019-128977
Copy DOI Journal: Blood |  Publication Date: Nov 13, 2019 |
 Citations: 34 |
Affiliation: Cincinnati Children's Hospital Medical Center, University of Southern California, National Cancer Institute, Children's Hospital of Philadelphia, St. Jude Children's Research Hospital, Baylor College of Medicine, Primary Children's Hospital, University of Utah, Johns Hopkins University, Children's Oncology Group, New York University, Children's Hospital Colorado, University of California, San FranciscoA Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
